Patent ID: 9382525
Filing Date: 2016-07-05
CPC Classification: A61K,C12N,C12Y

Claim Text:
1. A pharmaceutical composition for treating an arginine-dependent disease comprising a polyethylene glycol-arginase conjugate having a polyethylene glycol moiety covalently attached to a genetically-modified Sus scrofa arginase, wherein said genetically-modified Sus scrofa arginase has a single cysteine residue for covalently attaching to the polyethylene glycol moiety, wherein said single cysteine residue is located at a distance away from the active binding site of the genetically-modified Sus scrofa arginase such that the polyethylene glycol attachment does not interfere with the active site, wherein the polyethylene glycol moiety has a molecular weight of 10,000-30,000 Da, wherein the genetically-modified